NCT06634797

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,000 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 12 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1273.712	Intramuscular (IM) injection.
BIOLOGICAL	Placebo	Sodium chloride for IM injection.

Timeline

• Start date: 2024-10-08
• Primary completion: 2025-01-20
• Completion: 2025-01-20
• First posted: 2024-10-10
• Last updated: 2026-02-04
• Results posted: 2026-02-04

Locations

24 sites across 1 country: United States

Regulatory

• FDA-regulated drug study